Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies

Bibliography

• Bailey DG, Spence JD, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989;12:357-62
   PubMed Web of Science ®Google Scholar
• Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9
   PubMed Web of Science ®Google Scholar
• Saito M, Hirata-Koizumi M, Matsumoto M, et al. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005;28:677-94
   PubMed Web of Science ®Google Scholar
• Arts IC, Jacobs DR Jr, Harnack LJ, et al. Dietary catechins in relation to coronary heart disease death among postmenopausal women. Epidemiology 2001;12:668-75
   PubMed Web of Science ®Google Scholar
• Gorinstein S, Leontowicz H, Leontowicz M, et al. Changes in plasma lipid and antioxidant activity in rats as a result of naringin and red grapefruit supplementation. J Agric Food Chem 2005;53:3223-8
   PubMed Web of Science ®Google Scholar
• Mertens-Talcott SU, Zadezensky I, de Castro WV, et al. Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 2006;46:1390-416
   PubMed Web of Science ®Google Scholar
• Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992;18:1-29
   PubMed Web of Science ®Google Scholar
• Neurath AR, Strick N, Li YY, et al. Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide. BMC Infect Dis 2004;4:41
   PubMed Web of Science ®Google Scholar
• Delgoda R, Westlake AC. Herbal interactions involving cytochrome p450 enzymes: a mini review. Toxicol Rev 2004;23:239-49
   PubMedGoogle Scholar
• Hidaka M, Fujita K, Ogikubo T, et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004;32:581-3
   PubMed Web of Science ®Google Scholar
• Kim H, Yoon YJ, Shon JH, et al. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab Dispos 2006;34:521-3
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33(Suppl 2):10-6
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Patki KC, von Moltke LL, et al. Drug interactions with grapefruit juice: an update. J Clin Psychopharmacol 2001;21:357-9
   PubMed Web of Science ®Google Scholar
• Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 2004;58:S831-40
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Unadkat JD. Grapefruit juice, a glass full of drug interactions? Clin Pharmacol Ther 2007;81:631-3
   PubMed Web of Science ®Google Scholar
• Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33:518-23
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003;74:121-9
   PubMed Web of Science ®Google Scholar
• Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutr 2004;58:1-9
   PubMed Web of Science ®Google Scholar
• Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999;66:358-66
   PubMed Web of Science ®Google Scholar
• Lundahl J, Regardh CG, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995;49:61-7
   PubMed Web of Science ®Google Scholar
• Kakar SM, Paine MF, Stewart PW, et al. 6′7′-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004;75:569-79
   PubMed Web of Science ®Google Scholar
• Bailey DG, Kreeft JH, Munoz C, et al. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin Pharmacol Ther 1998;64:248-56
   PubMed Web of Science ®Google Scholar
• Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-90
   PubMed Web of Science ®Google Scholar
• de Castro WV, Mertens-Talcott S, Rubner A, et al. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 2006;54:249-55
   PubMed Web of Science ®Google Scholar
• Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997;7:391-6
   PubMedGoogle Scholar
• Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin 2004;25:129-36
   PubMed Web of Science ®Google Scholar
• He K, Iyer KR, Hayes RN, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9
   PubMed Web of Science ®Google Scholar
• Paine MF, Widmer WW, Hart HL, et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006;83:1097-105
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 2005;313:154-64
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Matsuo H, et al. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998;21:1062-6
   PubMed Web of Science ®Google Scholar
• Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999;48:543-52
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK, Leake BF, et al. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007;81:495-502
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Guo LQ, Fukuda K, et al. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000;378:356-63
   PubMed Web of Science ®Google Scholar
• Tian R, Koyabu N, Takanaga H, et al. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002;19:802-9
   PubMed Web of Science ®Google Scholar
• Honda Y, Ushigome F, Koyabu N, et al. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004;143:856-64
   PubMed Web of Science ®Google Scholar
• Soldner A, Christians U, Susanto M, et al. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999;16:478-85
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivisto KT, Backman JT, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998;64:655-60
   PubMed Web of Science ®Google Scholar
• Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ 2002;167:279-80
   PubMed Web of Science ®Google Scholar
• Ducharme P, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 2008;57:485-91
   Google Scholar
• Lilja JJ, Kivisto KT, Backman JT, et al. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000;56:411-5
   PubMed Web of Science ®Google Scholar
• Culm-Merdek KE, von Moltke LL, Gan L, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 2006;79:243-54
   PubMed Web of Science ®Google Scholar
• Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003;43:831-9
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53
   PubMed Web of Science ®Google Scholar
• Landahl S, Edgar B, Gabrielsson M, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clin Pharmacokinet 1988;14:374-83
   PubMed Web of Science ®Google Scholar
• Wade JR, Sambol NC. Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther 1995;57:569-81
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice–felodipine interaction in the elderly. Clin Pharmacol Ther 2000;68:28-34
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK, Kreeft JH, et al. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000;68:468-77
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 2005;61:337-40
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther 2004;75:184-90
   PubMed Web of Science ®Google Scholar
• Malhotra S, Bailey DG, Paine MF, et al. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14-23
   PubMed Web of Science ®Google Scholar
• Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-44
   PubMed Web of Science ®Google Scholar
• Di Marco MP, Edwards DJ, Wainer IW, et al. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002;71:1149-60
   PubMed Web of Science ®Google Scholar
• Grenier J, Fradette C, Morelli G, et al. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 2006;79:255-62
   PubMed Web of Science ®Google Scholar
• Guo LQ, Fukuda K, Ohta T, et al. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000;28:766-71
   PubMed Web of Science ®Google Scholar
• Egashira K, Ohtani H, Itoh S, et al. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos 2004;32:828-33
   PubMed Web of Science ®Google Scholar
• Xu J, Go ML, Lim LY. Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit, and pummelo. Pharm Res 2003;20:169-76
   PubMed Web of Science ®Google Scholar
• Lim SL, Lim LY. Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers. Int J Pharm 2006;307:42-50
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003;73:529-37
   PubMed Web of Science ®Google Scholar
• Siess MH, Leclerc J, Canivenc-Lavier MC, et al. Heterogenous effects of natural flavonoids on monooxygenase activities in human and rat liver microsomes. Toxicol Appl Pharmacol 1995;130:73-8
   PubMed Web of Science ®Google Scholar
• Buening MK, Chang RL, Huang MT, et al. Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981;41:67-72
   PubMed Web of Science ®Google Scholar
• Li Y, Wang E, Patten CJ, et al. Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. Drug Metab Dispos 1994;22:566-71
   PubMed Web of Science ®Google Scholar
• Backman JT, Maenpaa J, Belle DJ, et al. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin Pharmacol Ther 2000;67:382-90
   PubMed Web of Science ®Google Scholar
• Johnston PE, Milstone A. Probable interaction of bergamottin and cyclosporine in a lung transplant recipient. Transplantation 2005;79:746
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Johnston PE, Bailey DG, et al. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 2006;62:485-91
   PubMed Web of Science ®Google Scholar
• Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can J Urol 2002;9:1558-62
   PubMedGoogle Scholar
• Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis 2004;38:1413-9
   PubMed Web of Science ®Google Scholar
• McMurdo ME, Bissett LY, Price RJ, et al. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. Age Ageing 2005;34:256-61
   PubMed Web of Science ®Google Scholar
• Howell AB, Reed JD, Krueger CG, et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 2005;66:2281-91
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam: probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther 2007;81:833-9
   PubMed Web of Science ®Google Scholar
• Seeram NP, Adams LS, Hardy ML, et al. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem 2004;52:2512-7
   PubMed Web of Science ®Google Scholar
• Neto CC. Cranberry and blueberry: evidence for protective effects against cancer and vascular diseases. Mol Nutr Food Res 2007;51:652-64
   PubMed Web of Science ®Google Scholar
• Yan X, Murphy BT, Hammond GB, et al. Antioxidant activities and antitumor screening of extracts from cranberry fruit (Vaccinium macrocarpon). J Agric Food Chem 2002;50:5844-9
   PubMed Web of Science ®Google Scholar
• Neto CC. Cranberry and its phytochemicals: a review of in vitro anticancer studies. J Nutr 2007;137:S186-93
   PubMed Web of Science ®Google Scholar
• Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ 2003;327:1454
   PubMed Web of Science ®Google Scholar
• Pham DQ, Pham AQ. Interaction potential between cranberry juice and warfarin. Am J Health Syst Pharm 2007;64:490-4
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Perloff ES, et al. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 2006;79:125-33
   PubMed Web of Science ®Google Scholar
• Li Z, Seeram NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006;106:2057-61
   PubMed Web of Science ®Google Scholar
• Lansky EP, Jiang W, Mo H, et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 2005;23:11-20
   PubMed Web of Science ®Google Scholar
• Lansky EP, Harrison G, Froom P, et al. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs 2005;23:121-2
   PubMed Web of Science ®Google Scholar
• Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000;71:1062-76
   PubMed Web of Science ®Google Scholar
• Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001;158:195-8
   PubMed Web of Science ®Google Scholar
• Aviram M, Dornfeld L, Kaplan M, et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp Clin Res 2002;28:49-62
   PubMedGoogle Scholar
• Stupans L, Tan HW, Kirlich A, et al. Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J Pharm Pharmacol 2002;54:269-75
   PubMed Web of Science ®Google Scholar
• Tsukamoto S, Tomise K, Aburatani M, et al. Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa. J Nat Prod 2004;67:1839-41
   PubMed Web of Science ®Google Scholar
• Patel J, Buddha B, Dey S, et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004;11:262-77
   PubMedGoogle Scholar
• He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004;11:206-12
   PubMedGoogle Scholar
• von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004;56:1039-44
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hamilton SM, Stewart C, et al. Inhibition of liver microsomal cytochrome P450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res 1993;13:2341-6
   PubMed Web of Science ®Google Scholar
• Debersac P, Vernevaut MF, Amiot MJ, et al. Effects of a water-soluble extract of rosemary and its purified component rosmarinic acid on xenobiotic-metabolizing enzymes in rat liver. Food Chem Toxicol 2001;39:109-17
   PubMed Web of Science ®Google Scholar
• Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol 2007;47:286-94
   PubMed Web of Science ®Google Scholar
• Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33:644-8
   PubMed Web of Science ®Google Scholar
• Yeo C, Shon J, Liu K, et al. The effects of pomegranate juice on pharmacokinetics of simvastatin in healthy korean subjects. Clin Pharmacol Ther 2006;79:23
   PubMed Web of Science ®Google Scholar
• Nagata M, Hidaka M, Sekiya H, et al. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab Dispos 2007;35:302-5
   PubMed Web of Science ®Google Scholar
• Chang TK, Chen J, Lee WB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001;299:874-82
   PubMed Web of Science ®Google Scholar
• Fremont L. Biological effects of resveratrol. Life Sci 2000;66:663-73
   PubMed Web of Science ®Google Scholar
• Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 1999;262:20-4
   PubMed Web of Science ®Google Scholar
• Piver B, Berthou F, Dreano Y, et al. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91
   PubMed Web of Science ®Google Scholar
• Offman EM, Freeman DJ, Dresser GK, et al. Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001;70:17-23
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Yamada S, et al. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 2000;293:230-6
   PubMed Web of Science ®Google Scholar
• Lasker JM, Huang MT, Conney AH. In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J Pharmacol Exp Ther 1984;229:162-70
   PubMed Web of Science ®Google Scholar
• Ghosal A, Satoh H, Thomas PE, et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos 1996;24:940-7
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, von Moltke LL, et al. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 2002;302:1228-37
   PubMed Web of Science ®Google Scholar
• Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-97
   PubMedGoogle Scholar